Literature DB >> 2375645

Axillary dissection in melanoma. Prognostic variables in node-positive patients.

R G Bevilacqua1, D G Coit, A Rogatko, R N Younes, M F Brennan.   

Abstract

We evaluated the importance of 14 clinical and pathologic variables as determinants of prognosis in patients with malignant melanoma and positive regional lymph nodes at axillary dissection. The records of 197 patients operated on between 1974 and 1984 were reviewed. Univariate analysis indicated as prognostically significant the number (p less than 0.001) and percentage (p less than 0.001) of positive nodes, highest nodal status (p less than 0.001), macroscopic or microscopic nodal metastases (p = 0.002), presence or absence of extranodal disease (p = 0.003), clinical stage (III versus less than III, p = 0.015), and site (considered as trunk versus other locations, p = 0.02). However, by multivariate analysis, only three variables were shown to be independent determinants of survival: percentage of positive nodes (p = 0.004), presence or absence of extranodal disease (p = 0.012), and site (trunk versus other locations, p = 0.019). Combining these three variables, subsets of patients with markedly different prognoses could be generated. It is possible to predict a favorable outcome for patients with less than 10% positive nodes, no extranodal disease, and a primary lesion at a site other than the trunk. It is also possible to recognize that the prognosis is very poor for patients with extranodal disease and truncal primary lesions, regardless of the percentage of positive lymph nodes. Finally it was verified that the prognosis is always unfavorable when the percentage of positive lymph nodes is very high.

Entities:  

Mesh:

Year:  1990        PMID: 2375645      PMCID: PMC1358045          DOI: 10.1097/00000658-199008000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  RESULTS OF GROIN DISSECTION FOR MALIGNANT MELANOMA IN 220 PATIENTS.

Authors:  J G FORTNER; R J BOOHER; G T PACK
Journal:  Surgery       Date:  1964-04       Impact factor: 3.982

2.  Biostatistical basis of elective node dissection for malignant melanoma.

Authors:  J G Fortner; J Woodruff; D Schottenfeld; B Maclean
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

3.  Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis.

Authors:  J A Smith; J J Gamez-Araujo; H S Gallager; E C White; C M McBride
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

4.  Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.

Authors:  M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; S A Rosenberg
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.

Authors:  C Callery; A J Cochran; D J Roe; W Rees; S D Nathanson; J K Benedetti; R M Elashoff; D L Morton
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

7.  Results of ilioinguinal dissection for stage II melanoma.

Authors:  S J Finck; A E Giuliano; B D Mann; D L Morton
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

8.  Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes.

Authors:  C L Day; A J Sober; R A Lew; M C Mihm; T B Fitzpatrick; A W Kopf; M N Harris; S L Gumport; J W Raker; R A Malt; F M Golomb; A B Cosimi; W C Wood; P Casson; S Lopransi; F Gorstein; A Postel
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

9.  Prognosis of patients with pathologic stage II cutaneous malignant melanoma.

Authors:  D F Roses; J A Provet; M N Harris; S L Gumport; N Dubin
Journal:  Ann Surg       Date:  1985-01       Impact factor: 12.969

10.  The results of node resection for clinically enlarged lymph nodes in malignant melanoma.

Authors:  C R Rayner
Journal:  Br J Plast Surg       Date:  1981-04
View more
  8 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.

Authors:  Rebekah R White; Wilma E Stanley; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Treatment and outcomes of melanoma in acral location in Korean patients.

Authors:  Mi Ryung Roh; Jihyun Kim; Kee Yang Chung
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

5.  Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis.

Authors:  D G Coit; A Rogatko; M F Brennan
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

Review 6.  The role of sentinel lymph node biopsy in the management of melanoma.

Authors:  Farin Amersi; Donald L Morton
Journal:  Adv Surg       Date:  2007

7.  Intraoperative application of fibrin sealant does not reduce the duration of closed suction drainage following radical axillary lymph node dissection in melanoma patients: a prospective randomized trial in 58 patients.

Authors:  Heiko Neuss; Wieland Raue; Gerold Koplin; Wolfgang Schwenk; Christian Reetz; Julian W Mall
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

8.  Adjuvant radiation therapy in metastatic lymph nodes from melanoma.

Authors:  Jean-Emmanuel Bibault; Sylvain Dewas; Xavier Mirabel; Laurent Mortier; Nicolas Penel; Luc Vanseymortier; Eric Lartigau
Journal:  Radiat Oncol       Date:  2011-02-06       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.